Rhythmlink: Rethinking EEG Electrodes
healthcaretechoutlook

Rhythmlink: Rethinking EEG Electrodes

Follow Rhythmlink on :

Leah Hanson, VP of Global Sales & Marketing, RhythmlinkLeah Hanson, VP of Global Sales & Marketing, Rhythmlink
Measuring and studying brainwaves using electroencephalography (EEG) has always been the clinical standard of care for diagnosing a patient’s neurological condition. Although EEG devices have gone through several iterations since its invention nearly a century ago, they are still unable to improve patient compliance due in part to their reusable metal-based EEG electrodes. According to a multicenter study, reusable EEG electrodes attached to a patient’s scalp are a source of microorganisms that can lead to hospital-acquired infections (HAIs). An excerpt of the study notes, “Out of the 124 swabs from the electrodes that yielded favorable patient scans, around 25 percent were found to have positive bacterial cultures.”

So, the question arises—how does one bridge this healthcare complications gap and usher in a more sophisticated patient care process? Columbia, SC-based medical device manufacturing company Rhythmlink has the answer with its FDA-cleared, first-of-its-kind portfolio of disposable EEG electrodes. The disposable nature of Rhythmlink’s electrode makes it a nonpareil choice for eliminating instances of HAIs, thus upending a century-old, archaic EEG practice.

Rhythmlink entered the medical device market with its FDA-approved subdermal needles designed for the intraoperative monitoring surgical suite. In 2013, the company developed the first disposable EEG electrode, cleared by the FDA as MR conditional for 1.5T and 3T MR scans. Today, Rhythmlink’s slew of disposable EEG electrodes is setting a new benchmark in the medical devices segment by offering high-quality brainwave readings and increased patient comfort in a safe and cost-efficient manner.

“At the core of our product portfolio is our emphasis on better connecting patients to machines,” says Leah Hanson, VP of sales and marketing at Rhythmlink.

With an innovative and intuitive design, Rhythmlink’s EEG electrodes can be operated by a bedside clinician or an EEG technician to conduct scans. Additionally, Rhythmlink’s disposable silver chloride-based EEG electrodes provide excellent data quality between a patient’s skin and the conducting surface of the electrode and, more importantly, alleviate the chances of skin breakdown and irritation.

Highlighting Rhythmlink’s potency in improving patient care outcomes is a client success story where a hospital used Rhythmlink’s EEG devices for a pediatric patient. Initially, the patient—who was repeatedly admitted due to breakthrough seizures—was experiencing extreme skin discomfort because of the metal-based EEG electrodes. Together with that, because of the constant re-application of the electrodes, the patient was at an increased risk of sustaining HAIs and other complications. With Rhythmlink’s specially-designed FDA Cleared MR Conditional disposable EEG electrodes, clinicians could attach and leave EEG electrodes on the patient for longer periods during their stay at the hospital without any signs of irritations. As a result, the patient displayed improved skin health when compared to previous hospital admissions.

Besides improving intraoperative neurophysiological monitoring (IONM) and skin health for critical care, Rhythmlink’s EEG electrodes are also a technological marvel when it comes to diagnostic tests for sleep disorders. The risk-free, disposable electrodes minimize the chances of cross-contamination among patients, thereby enhancing the accuracy of polysomnography tests. “At the same time, our EEG electrodes are a boon for sleep centers and sleep laboratories that can now effortlessly comply with the Joint Commission standards while conducting sleep studies,” informs Hanson.

Displaying such robustness, today, Rhythmlink has claimed the position of an “avant-garde” medical device manufacturing company. Their culture of innovation is also portrayed in Rhythmlink’s enthusiasm to work with OEM partners for designing customized products, offering private labeling, and executing regulatory tasks, among other functions. Striding ahead, the company is keen on partnering with many multi-disciplinary technology experts to add new dimensions to its EEG electrode portfolio. Hanson strongly believes that Rhythmlink’s leading edge, user-friendly, and disposable EEG electrodes are leading the way in advancing the overall medical devices industry and boosting value-based patient care.

Share this Article:
Rhythmlink

Company
Rhythmlink

Headquarters
Columbia, SC

Management
Leah Hanson, VP of Global Sales & Marketing

Description
South Carolina-based Rhythmlink Designs, manufactures, and distributes customized, cost-effective medical devices that aid caregivers in better understanding neurological and sleep-related disorders to deliver holistic value to the patient care process. Rhythmlink’s portfolio comprises products that are specifically designed to enhance the operations in IOM, operating rooms, emergency rooms, and intensive care units. The company’s IOM product line consists of electrodes tailored to augment the workflow efficiency in IOM. Besides, the ER and ICU designs of the company’s electrodes does not require a registered EEG technologist to apply the product on a patient’s scalp and ensure the quick and reliable generation of high quality data. And with Rhythmlink’s diagnostic line is utilized by its clients for polysomnography

Rhythmlink News

Rhythmlink Announces Investment Partnership with New Heritage

COLUMBIA, S.C.: Rhythmlink International, LLC is pleased to announce an exciting new investment partnership with New Heritage Capital, a Boston-based private equity firm that specializes in growing founder-owned businesses.

As a market leading designer and manufacturer of disposable neurodiagnostic devices and consumables, Rhythmlink is quickly growing, and an investment from Heritage will ensure that growth continues along with the innovation and quality that Rhythmlink is known for. Heritage completed its investment via its unique Private IPO® solution, which leaves operating control in the hands of the reinvesting founders while providing them the desired liquidity and financial flexibility to accelerate growth into the future. The investment was completed on February 19, 2019.

“We chose to partner with Heritage because of their experience in backing founder-owned businesses and investing in healthcare, but most importantly because their investment structure enabled us to retain operating control,” said Shawn Regan, CEO and Co-Founder. Michael O’Leary, COO and Co-Founder, added, “The culture we have built with our employees at Rhythmlink and our reputation in the marketplace are incredibly important to us. We wanted a partnership that would ensure this would stay intact.”

Melissa Barry, Partner at Heritage added, “We are thrilled to partner with Shawn, Michael and the entire Rhythmlink team to help them accelerate growth, continue to develop innovative products and provide customers with the highest level of quality and service. Rhythmlink is a high-growth business with an incredible amount of opportunity to further expand the applicability of neuro and brain health monitoring throughout the healthcare continuum. We are excited about what the future will bring.”